Literature DB >> 11683961

Characterization of glycosylphosphatidylinositol-anchored decay accelerating factor (GPI-DAF) and transmembrane DAF gene expression in wild-type and GPI-DAF gene knockout mice using polyclonal and monoclonal antibodies with dual or single specificity.

T Miwa1, X Sun, R Ohta, N Okada, C L Harris, B P Morgan, W C Song.   

Abstract

Decay-accelerating factor (DAF, CD55) is a glycosylphosphatidylinositol (GPI)-linked membrane inhibitor of complement activation. While human and other mammalian species contain only one DAF gene, two distinct DAF genes, referred to as GPI-DAF and transmembrane (TM)-DAF, respectively, have been identified in the mouse. Using several independently generated monoclonal and polyclonal antibodies, either with dual or single specificity for GPI-DAF and TM-DAF gene products, we have examined the expression of the two DAF genes in tissues of the wild-type and a strain of knockout mouse whose GPI-DAF gene has been inactivated. By fluorescence-activated cell sorting (FACS) analysis, we found that DAF protein is present on the wild-type mouse erythrocytes and lymphocytes but no signal was detectable on the same cells of GPI-DAF gene knockout mice. Both T and B lymphocytes and splenic macrophages express the GPI-DAF gene but the expression level is higher on B lymphocytes than on T lymphocytes. Within the T cell population, both CD4+ and CD8+ T cells are positive. DAF protein was detected by immunohistochemistry at high levels on wild-type mouse spermatids and mature sperm. In contrast, only mature sperm stained positive in the GPI-DAF gene knockout mouse testis, suggesting that GPI-DAF but not the TM-DAF gene is expressed on spermatids. Examination of the fetoplacental unit at the day 7.5 stage revealed that GPI-DAF but not the TM-DAF gene is expressed in the maternal decidua cells surrounding the trophoectoderm of the embryo. No DAF expression was detected on trophoblast or the embryo proper. These findings suggest that although the TM-DAF gene is irrelevant on mouse blood cells, the two DAF genes may have different roles in germ cell development and/or mature sperm function. Because complement receptor 1-related gene/protein y (Crry) has been shown to be expressed on early mouse embryos, the complete lack of GPI-DAF and TM-DAF gene expression in early mouse development may explain the observed sensitivity of Crry-deficient embryos to maternal complement attack.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11683961      PMCID: PMC1783299          DOI: 10.1046/j.1365-2567.2001.01280.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  32 in total

1.  A critical role for murine complement regulator crry in fetomaternal tolerance.

Authors:  C Xu; D Mao; V M Holers; B Palanca; A M Cheng; H Molina
Journal:  Science       Date:  2000-01-21       Impact factor: 47.728

2.  Molecular cloning and characterization of mouse CD97.

Authors:  J Hamann; C van Zeventer; A Bijl; C Molenaar; K Tesselaar; R A van Lier
Journal:  Int Immunol       Date:  2000-04       Impact factor: 4.823

3.  Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55).

Authors:  Y M Qian; M Haino; K Kelly; W C Song
Journal:  Immunology       Date:  1999-10       Impact factor: 7.397

Review 4.  Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases.

Authors:  T Miwa; W C Song
Journal:  Int Immunopharmacol       Date:  2001-03       Impact factor: 4.932

5.  Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor.

Authors:  M E Medof; T Kinoshita; R Silber; V Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

6.  Molecular cloning of murine decay accelerating factor by immunoscreening.

Authors:  Y Fukuoka; A Yasui; N Okada; H Okada
Journal:  Int Immunol       Date:  1996-03       Impact factor: 4.823

7.  The presence of complement in human cervical mucus and its possible relevance to infertility in women with complement-dependent sperm-immobilizing antibodies.

Authors:  R J Price; B Boettcher
Journal:  Fertil Steril       Date:  1979-07       Impact factor: 7.329

8.  Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.

Authors:  A Nicholson-Weller; J P March; S I Rosenfeld; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1983-08       Impact factor: 11.205

9.  Decay-accelerating factor functions as a signal transducing molecule for human T cells.

Authors:  L S Davis; S S Patel; J P Atkinson; P E Lipsky
Journal:  J Immunol       Date:  1988-10-01       Impact factor: 5.422

Review 10.  Paroxysmal nocturnal haemoglobinuria.

Authors:  W F Rosse; C J Parker
Journal:  Clin Haematol       Date:  1985-02
View more
  18 in total

1.  Immature recent thymic emigrants are eliminated by complement.

Authors:  Fan-Chi Hsu; Michael J Shapiro; Meibo W Chen; Douglas C McWilliams; Lauren M Seaburg; Sarah N Tangen; Virginia Smith Shapiro
Journal:  J Immunol       Date:  2014-11-03       Impact factor: 5.422

2.  Depletion of complement does not impact initiation of xenobiotic-induced autoimmune disease.

Authors:  David M Cauvi; Christopher B Toomey; K Michael Pollard
Journal:  Immunology       Date:  2012-04       Impact factor: 7.397

3.  The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice.

Authors:  B P Morgan; J Chamberlain-Banoub; J W Neal; W Song; M Mizuno; C L Harris
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

4.  Constitutive expression of murine decay-accelerating factor 1 is controlled by the transcription factor Sp1.

Authors:  David M Cauvi; Gabrielle Cauvi; K Michael Pollard
Journal:  J Immunol       Date:  2006-09-15       Impact factor: 5.422

5.  Decay-accelerating factor induction by tumour necrosis factor-alpha, through a phosphatidylinositol-3 kinase and protein kinase C-dependent pathway, protects murine vascular endothelial cells against complement deposition.

Authors:  Saifur R Ahmad; Elaine A Lidington; Rieko Ohta; Noriko Okada; Michael G Robson; Kevin A Davies; Michael Leitges; Claire L Harris; Dorian O Haskard; Justin C Mason
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

6.  Decay accelerating factor is essential for successful corneal engraftment.

Authors:  A Esposito; B Suedekum; J Liu; F An; J Lass; M G Strainic; F Lin; P Heeger; M E Medof
Journal:  Am J Transplant       Date:  2010-01-05       Impact factor: 8.086

7.  Decay-accelerating factor ameliorates systemic autoimmune disease in MRL/lpr mice via both complement-dependent and -independent mechanisms.

Authors:  Takashi Miwa; Michael A Maldonado; Lin Zhou; Koei Yamada; Gary S Gilkeson; Robert A Eisenberg; Wen-Chao Song
Journal:  Am J Pathol       Date:  2007-04       Impact factor: 4.307

8.  Deficiency of decay-accelerating factor and complement receptor 1-related gene/protein y on murine platelets leads to complement-dependent clearance by the macrophage phagocytic receptor CRIg.

Authors:  David D Kim; Takashi Miwa; Yuko Kimura; Reto A Schwendener; Menno van Lookeren Campagne; Wen-Chao Song
Journal:  Blood       Date:  2008-06-04       Impact factor: 22.113

9.  Complement-dependent T-cell lymphopenia caused by thymocyte deletion of the membrane complement regulator Crry.

Authors:  Takashi Miwa; Lin Zhou; Yuko Kimura; David Kim; Avinash Bhandoola; Wen-Chao Song
Journal:  Blood       Date:  2009-01-09       Impact factor: 22.113

10.  Focal and segmental glomerulosclerosis induced in mice lacking decay-accelerating factor in T cells.

Authors:  Lihua Bao; Mark Haas; Jeffrey Pippin; Ying Wang; Takashi Miwa; Anthony Chang; Andrew W Minto; Miglena Petkova; Guilin Qiao; Wen-Chao Song; Charles E Alpers; Jian Zhang; Stuart J Shankland; Richard J Quigg
Journal:  J Clin Invest       Date:  2009-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.